Nyxoah S.A (NYXH): רווח למניה בשנים עשר החודשים האחרונים

Demand for neurostimulation for apnea is growing in Europe, although expansion in the US is limited by FDA regulations. The rolling annual revenue per share slice on the GURU.Markets chart confirms that the metric is holding at -2.00. Nyxoah S.A. (NYXH) ensures high margins and a stable cash flow through its unique micro-implants. Experienced management with a scientific foundation is effectively scaling the technology on a global level.
פילוחים אנליטיים של חברת Nyxoah S.A. (NYXH)

For Nyxoah S.A. (NYXH), which implements neurostimulators for the treatment of apnea, the trailing 12-month net income per share on GURU.Markets demonstrates the monetization efficiency of high-tech solutions for clinics. This indicator is calculated by dividing the total annual profit by the total number of shares, allowing investors to assess the real return on each security regardless of short-term market fluctuations.